Literature DB >> 17437704

PLK1 inhibitors: setting the mitotic death trap.

Simon Plyte1, Andrea Musacchio.   

Abstract

Polo-like kinase 1 (Plk1) regulates mitotic progression in all eukaryotes and has been implicated in the transformation of human cells. Analysis of the cytological and anti-tumor activities of BI 2536, a novel, selective pharmacological inhibitor of Plk1, has connected chemistry and biology to the bedside.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17437704     DOI： 10.1016/j.cub.2007.02.018

Source DB:  PubMed          Journal:  Curr Biol        ISSN： 0960-9822            Impact factor:   10.834


  8 in total

1.  Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1).

Authors:  Yu-Chen Chang; Chu-Hen Wu; Tzu-Chen Yen; Pin Ouyang
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

2.  The Plk1-dependent phosphoproteome of the early mitotic spindle.

Authors:  Anna Santamaria; Bin Wang; Sabine Elowe; Rainer Malik; Feng Zhang; Manuel Bauer; Alexander Schmidt; Herman H W Silljé; Roman Körner; Erich A Nigg
Journal:  Mol Cell Proteomics       Date:  2010-09-22       Impact factor: 5.911

3.  In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.

Authors:  María Sol Brassesco; Julia Alejandra Pezuk; Andressa Gois Morales; Jaqueline Carvalho de Oliveira; Gabriela Molinari Roberto; Glenda Nicioli da Silva; Harley Francisco de Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Cancer Biol Ther       Date:  2013-05-31       Impact factor: 4.742

4.  RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis.

Authors:  Victoria Sherwood; Ria Manbodh; Carol Sheppard; Andrew D Chalmers
Journal:  Mol Biol Cell       Date:  2008-02-13       Impact factor: 4.138

5.  A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.

Authors:  Surojit Sur; Raymond Pagliarini; Fred Bunz; Carlo Rago; Luis A Diaz; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-18       Impact factor: 11.205

6.  Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.

Authors:  Samuel Wolf; Jana Lorenz; Joachim Mössner; Marcus Wiedmann
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

7.  Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks.

Authors:  Paul J Scutt; Matthew L H Chu; Dominic A Sloane; Mike Cherry; Colin R Bignell; David H Williams; Patrick A Eyers
Journal:  J Biol Chem       Date:  2009-04-09       Impact factor: 5.157

8.  Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer.

Authors:  M Loddo; S R Kingsbury; M Rashid; I Proctor; C Holt; J Young; S El-Sheikh; M Falzon; K L Eward; T Prevost; R Sainsbury; K Stoeber; G H Williams
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.